Cardiac magnetic resonance (CMR) it is a technique without radiation, which is considered the gold-standard for the evaluation of cardiac anatomy, function and even tissue composition. The RESILIENCE trial will use CMR as the main outcome measure methodology, and patients enrolled in the trial will undergo 3 scans across the duration of the study.
Multinational, prospective, proof of concept phase II, double-blinded, sham-controlled, randomized clinical trial (RCT) to evaluate the efficacy and safety of Remote Ischaemic Conditioning (RIC) in Lymphoma patients receiving anthracyclines. Patients scheduled to undergo ≥5 chemotherapy cycles will be eligible.
GCOS 2023 Symposium Proceedings: JACC: CardioOncology State-of-the-Art Review Despite improvements in cancer survival, cancer therapy–related cardiovascular toxicity has risen to become a prominent clinical challenge. This has led to the growth of the burgeoning field of cardio-oncology, which aims to advance the cardiovascular health of cancer patients and survivors, through
This article is authored by 2 PIs of RESILIENCE (María Gomes-Silva from IPO Lisbon & Borja Ibanez from CNIC Spain). This editorial summarizes the results of the 2 first trials testing remote ischemic conditioning in the context of anthracycline cardiotoxicity. In this article, the 2 trials are described and their
The Hatter Cardiovascular Institute biennial workshop, originally scheduled for April 2020 but postponed for 2 years due to the Covid pandemic, was organised to debate and discuss the future of Remote Ischaemic Conditioning (RIC). This evolved from the large multicentre CONDI-2–ERIC–PPCI outcome study which demonstrated no additional benefit when using
There is a strong need to identify (bio)markers that can detect early stages of anthracycline-induced cardiotoxicity (AIC). In this editorial, 2 RESILIENCE researchers present the current state of the art of the field. They discuss data from al original paper published in the same issue of the journal by Bonny
By using a highly translatable large-animal model, this work shows that cumulative exposure to anthracycline results in an irreversible damage to the heart microcirculation. The microcirculation injury is observed even before overt left ventricular cardiac systolic dysfunction (surrogate for overt cardiotoxicity) is present. Cardiac microcirculation damage is associated with poor
Editorial article highlighting the strong potential of remote ischemic conditioning to prevent anthracycline-induced cardiotoxicity. This intervention will be tested within RESILIENCE project.
